Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

17:03
10/09/16
10/09
17:03
10/09/16
17:03

Merck reports data from KEYNOTE-024, KEYNOTE-021

Merck announced results from two studies of KEYTRUDA in the first-line treatment of patients with metastatic non-small cell lung cancer at the ESMO 2016 Congress. In KEYNOTE-024, which evaluated squamous and non-squamous NSCLC patients whose tumors expressed high levels of PD-L1, KEYTRUDA provided a 50 percent reduction in the risk of disease progression or death and a 40 percent reduction in the risk of death compared to platinum doublet, the current standard of care. The median follow-up was 11.2 months. The median PFS for KEYTRUDA was 10.3 months compared to 6.0 months for chemotherapy. At six months, 62.1 percent of patients treated with KEYTRUDA were alive and had no disease progression compared to 50.3 percent of those receiving chemotherapy. This benefit was observed in all study subgroups. ORR was 44.8 percent for patients receiving KEYTRUDA, including six complete responses, compared to 27.8 percent with chemotherapy, including one complete response. The median duration of response was not reached with KEYTRUDA, with a range of 1.9+ to 14.5+ months. The median duration of response with the chemotherapy group was 6.3 months. Median time to response was 2.2 months for both groups. The safety of KEYTRUDA was consistent with what has been seen in previous trials among patients with metastatic NSCLC. There was one treatment-related death in a patient receiving KEYTRUDA -- cause unknown. In KEYNOTE-021, Cohort G, which included patients with metastatic non-squamous NSCLC regardless of PD-L1 expression level, KEYTRUDA plus chemotherapy -- carboplatin plus pemetrexed -- achieved a 55 percent objective response rate compared to 29 percent for chemotherapy alone, the standard of care, and reduced the risk of disease progression or death by 47 percent. All responses were partial. Median duration of response was not reached in either group, with a range of 1.4+-13.0+ for KEYTRUDA plus chemotherapy and 1.4+-15.2+ for chemotherapy alone. Responses in both groups were durable, with 88 percent of responders in the KEYTRUDA plus chemotherapy group and 78 percent of responders in the chemotherapy alone group experiencing ongoing response at the time of data cut-off. Additionally, the KEYTRUDA combination significantly reduced the risk of disease progression or death compared to chemotherapy alone. Median PFS was 13.0 months with KEYTRUDA plus chemotherapy compared to 8.9 months with chemotherapy alone. OS was similar between the two arms, with 92 percent survival at six months in both, and 75 percent and 72 percent survival at 12 months in the KEYTRUDA combination and chemotherapy alone, respectively. Of treated patients on the KEYTRUDA plus chemotherapy arm, 47 percent remained on treatment as of the cut-off date, compared to 31 percent on chemotherapy alone. Of the treated patients who discontinued treatment on the chemotherapy-only arm, 52 percent subsequently received anti-PD-L1 therapy, with 32 percent crossing over to KEYTRUDA monotherapy as allowed by the study protocol and 19 percent receiving it outside of study crossover. The most common immune-mediated adverse events in patients receiving KEYTRUDA plus chemotherapy were hypothyroidism and hyperthyroidism. Additionally, pneumonitis, infusion reactions, and severe skin toxicity were noted. These immune-mediated adverse events occurred at similar rates to patients receiving KEYTRUDA as a single agent. There was one treatment-related death from sepsis in a patient receiving KEYTRUDA plus chemotherapy, and two -- one from sepsis and one from pancytopenia -- in patients receiving chemotherapy alone.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

NVS

Novartis

$74.61

1.21 (1.65%)

, KO

Coca-Cola

$43.28

0.21 (0.49%)

20:25
04/24/17
04/24
20:25
04/24/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$74.61

1.21 (1.65%)

KO

Coca-Cola

$43.28

0.21 (0.49%)

MMM

3M

$194.23

2.73 (1.43%)

MCD

McDonald's

$134.23

0.82 (0.61%)

LMT

Lockheed Martin

$276.21

3.12 (1.14%)

DD

DuPont

$79.37

0.72 (0.92%)

BIIB

Biogen

$276.86

3.92 (1.44%)

CAT

Caterpillar

$96.81

2.49 (2.64%)

VLO

Valero

$66.82

1.59 (2.44%)

GLW

Corning

$27.52

0.5 (1.85%)

BHI

Baker Hughes

$58.65

0.97 (1.68%)

PCAR

PACCAR

$67.73

1.97 (3.00%)

NTRS

Northern Trust

$89.38

2.02 (2.31%)

FITB

Fifth Third

$25.33

0.71 (2.88%)

FCX

Freeport McMoRan

NLSN

Nielsen

$41.59

0.59 (1.44%)

CNC

Centene

$71.99

1.35 (1.91%)

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

JBLU

JetBlue

$21.75

0.22 (1.02%)

XRX

Xerox

$7.06

0.14 (2.02%)

PII

Polaris Industries

$83.14

1.28 (1.56%)

AN

AutoNation

$44.06

1.25 (2.92%)

GPK

Graphic Packaging

$13.58

0.04 (0.30%)

RAD

Rite Aid

$3.73

-0.07 (-1.84%)

TUP

Tupperware Brands

$65.69

1.47 (2.29%)

EAT

Brinker

$45.46

0.8 (1.79%)

AKS

AK Steel

$7.12

0.4 (5.95%)

SVU

Supervalu

$3.85

0.01 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

  • 23

    May

  • 24

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 20

    Jun

  • 26

    Jun

WBS

Webster Financial

$51.26

1 (1.99%)

19:50
04/24/17
04/24
19:50
04/24/17
19:50
Hot Stocks
Webster Financial raises quarterly dividend by 1c to 26c per share »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

19:42
04/24/17
04/24
19:42
04/24/17
19:42
Periodicals
Trump seeks 15% corporate tax rate, WSJ says »

President Donald Trump…

RYN

Rayonier

$28.81

-0.03 (-0.10%)

, LL

Lumber Liquidators

$22.66

-0.39 (-1.69%)

19:34
04/24/17
04/24
19:34
04/24/17
19:34
Periodicals
White House to impose tariffs on Canadian lumber, FT says »

The Trump administration…

RYN

Rayonier

$28.81

-0.03 (-0.10%)

LL

Lumber Liquidators

$22.66

-0.39 (-1.69%)

DEL

Deltic Timber

$76.76

0.44 (0.58%)

WY

Weyerhaeuser

$34.89

0.33 (0.95%)

OSB

Norbord

$29.90

0.02 (0.07%)

PCH

Potlatch

$47.05

0.25 (0.53%)

UFPI

Universal Forest

$96.21

0.89 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 04

    May

  • 04

    May

AAPL

Apple

$143.64

1.37 (0.96%)

, DLB

Dolby

$52.58

1.01 (1.96%)

19:20
04/24/17
04/24
19:20
04/24/17
19:20
Periodicals
Apple taps NASA AR specialist to help run own AR efforts, Bloomberg says »

Apple (AAPL) has tapped…

AAPL

Apple

$143.64

1.37 (0.96%)

DLB

Dolby

$52.58

1.01 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

AMZN

Amazon.com

$907.41

8.88 (0.99%)

, AAPL

Apple

$143.64

1.37 (0.96%)

19:18
04/24/17
04/24
19:18
04/24/17
19:18
Periodicals
Spotify job listings hint at hardware effort, Business Insider reports »

Music streaming service…

AMZN

Amazon.com

$907.41

8.88 (0.99%)

AAPL

Apple

$143.64

1.37 (0.96%)

SNAP

Snap

$21.20

0.27 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 10

    May

  • 16

    May

  • 23

    May

ORCL

Oracle

$44.84

0.41 (0.92%)

19:09
04/24/17
04/24
19:09
04/24/17
19:09
Periodicals
Oracle creating internal 'startup' to work on new tech, Bloomberg reports »

Oracle is creating a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

MET

MetLife

$52.02

0.75 (1.46%)

18:57
04/24/17
04/24
18:57
04/24/17
18:57
Periodicals
MetLife seeks delay of SIFI case after Trump orders review, Bloomberg says »

MetLife has asked a court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 13

    Jun

NGL

NGL Energy Partners

$21.70

0.1 (0.46%)

18:38
04/24/17
04/24
18:38
04/24/17
18:38
Hot Stocks
NGL Energy Partners sees FY18 adjusted EBITDA $500M-$525M »

For FY18, NGL expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGL

NGL Energy Partners

$21.70

0.1 (0.46%)

18:37
04/24/17
04/24
18:37
04/24/17
18:37
Earnings
NGL Energy Partners sees FY17 adjusted EBITDA $380M »

Based upon preliminary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$130.40

0.44 (0.34%)

18:20
04/24/17
04/24
18:20
04/24/17
18:20
Periodicals
Kimberly-Clark priced for perfection, Barron's reports »

Kimberly-Clark reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 31

    May

DKL

Delek Logistics

18:16
04/24/17
04/24
18:16
04/24/17
18:16
Hot Stocks
Delek Logistics raises quarterly cash distribution 1.5% to 69c per share »

Delek Logistics Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

APU

AmeriGas

$45.83

0.04 (0.09%)

18:10
04/24/17
04/24
18:10
04/24/17
18:10
Hot Stocks
AmeriGas raises dividend 1c to 95c »

Directors of AmeriGas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

, MKGAY

Merck KGaA

$37.91

1.2299 (3.35%)

18:08
04/24/17
04/24
18:08
04/24/17
18:08
Hot Stocks
Merck KGaA divests Biosimilars unit to Fresenius »

Merck KGaA (MKGAY) …

FSNUY

Fresenius SE

$20.56

0.89 (4.52%)

MKGAY

Merck KGaA

$37.91

1.2299 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCOM

National Commerce

$37.90

0.15 (0.40%)

18:03
04/24/17
04/24
18:03
04/24/17
18:03
Hot Stocks
National Commerce, Patriot bank sign merger agreement »

National Commerce, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NCOM

National Commerce

$37.90

0.15 (0.40%)

18:02
04/24/17
04/24
18:02
04/24/17
18:02
Earnings
National Commerce reports Q1 EPS 45c, consensus 35c »

Reports Q1 NIM 4.18% vs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NFLX

Netflix

$143.83

0.96 (0.67%)

, FB

Facebook

$145.47

1.79 (1.25%)

17:58
04/24/17
04/24
17:58
04/24/17
17:58
Periodicals
FCC chairman expected to reveal net neutrality plans Wednesday, WSJ says »

FCC chairman Ajit Pai is…

NFLX

Netflix

$143.83

0.96 (0.67%)

FB

Facebook

$145.47

1.79 (1.25%)

AMZN

Amazon.com

$907.41

8.88 (0.99%)

GOOG

Alphabet

$862.76

19.57 (2.32%)

GOOGL

Alphabet Class A

$878.93

19.98 (2.33%)

CMCSA

Comcast

$38.01

-0.15 (-0.39%)

CMCSK

Comcast

VZ

Verizon

$47.05

-0.2 (-0.42%)

T

AT&T

$40.02

0.09 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 22

    May

  • 23

    May

  • 05

    Jun

MSFT

Microsoft

$67.53

1.13 (1.70%)

, GOOG

Alphabet

$862.76

19.57 (2.32%)

17:48
04/24/17
04/24
17:48
04/24/17
17:48
Periodicals
Microsoft possibly eyes education push, 'CloudBook' system, Windows Central says »

Microsoft (MSFT) may be…

MSFT

Microsoft

$67.53

1.13 (1.70%)

GOOG

Alphabet

$862.76

19.57 (2.32%)

GOOGL

Alphabet Class A

$878.93

19.98 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 22

    May

KMG

KMG Chemicals

$45.09

0.49 (1.10%)

17:47
04/24/17
04/24
17:47
04/24/17
17:47
Hot Stocks
KMG Chemicals to acquire Flowchem for $495M in cash »

KMG announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMG

KMG Chemicals

$45.09

0.49 (1.10%)

17:46
04/24/17
04/24
17:46
04/24/17
17:46
Hot Stocks
Breaking Hot Stocks news story on KMG Chemicals »

KMG Chemicals to acquire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UIS

Unisys

$11.15

0.2 (1.83%)

, LLNW

Limelight Networks

$2.75

0.1 (3.77%)

17:43
04/24/17
04/24
17:43
04/24/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Unisys…

UIS

Unisys

$11.15

0.2 (1.83%)

LLNW

Limelight Networks

$2.75

0.1 (3.77%)

LXU

LSB Industries

$7.35

0.18 (2.51%)

SLCA

U.S. Silica

$41.55

1.04 (2.57%)

RRC

Range Resources

$27.23

-0.24 (-0.87%)

SANM

Sanmina

$39.95

1.35 (3.50%)

AA

Alcoa

$33.31

1.61 (5.08%)

IDRA

Idera Pharmaceuticals

$2.25

-0.07 (-3.02%)

HUM

Humana

$213.76

0.09 (0.04%)

ICHR

Ichor Holdings

$18.93

0.57 (3.10%)

CVS

CVS Health

$80.05

0.77 (0.97%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

ANTM

Anthem

$168.41

0.61 (0.36%)

CDNS

Cadence Design

$33.48

0.6 (1.82%)

ABX

Barrick Gold

$19.04

-0.19 (-0.99%)

ZION

Zions Bancorp

$41.96

1.11 (2.72%)

CNI

Canadian National

$75.66

0.94 (1.26%)

WHR

Whirlpool

$174.80

3.29 (1.92%)

CTRV

ContraVir Pharmaceuticals

$1.18

-0.23 (-16.31%)

KPTI

Karyopharm

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 10

    May

  • 16

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 13

    Jun

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

NWN

Northwest Natural Gas

$60.45

0.45 (0.75%)

17:43
04/24/17
04/24
17:43
04/24/17
17:43
Hot Stocks
Northwest Natural Gas appoints Frank Burkhartsmeyeras CFO »

NW Natural has hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

RTN

Raytheon

$156.03

1.99 (1.29%)

17:41
04/24/17
04/24
17:41
04/24/17
17:41
Hot Stocks
Raytheon awarded $111.3M government contract »

Raytheon Co., Integrated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

GABC

German American Bancorp

$33.49

-15.7 (-31.92%)

17:39
04/24/17
04/24
17:39
04/24/17
17:39
Hot Stocks
German American Bancorp raises quarterly dividend to 13c per share »

The company announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRBA

First Bank

$13.35

-0.15 (-1.11%)

17:39
04/24/17
04/24
17:39
04/24/17
17:39
Hot Stocks
First Bank reports Q1 book value per share $7.95 »

Reports Q1 net loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.